Table 1.

Results of the ddPCR and targeted amplicon sequencing.

Patient IDTumor typeddPCR measurementAmpSeq measurement
ddPCR targeted mutationcfDNA, ng/mLMutant allele, copies/mLMutant AFAmpSeq targeted mutationMutant AF
CSFPlasmaCSFPlasmaCSFPlasmaCSFPlasma
S1Vestibular schwannomaNF2 p.R57*2.13.2000.0000.000NF2 p.R57*0.0000.000
S2Atypical meningiomaAKT1 p.E17Ka2.421.43200.0400.000AKT1 p.E17KNPbNP
S3Brain metastases from melanomaBRAF p.V600E0.37.7700.0740.000BRAF p.V600ENPNP
S4Brain metastases from melanomaNRAS p.Q61L3.31.631170.0030.214NRAS p.Q61LNPNP
S5Brain metastases from colon adenocarcinomaKRAS p.G12D18.18.7296340.4920.002TP53 p.R282W0.6540.000
S6Brain metastases from lung adenocarcinomaEGFR p.L585R0.54.736930.0200.445EGFR p.L585R0.015NA
S7Brain metastases from lung adenocarcinomaEGFR p.E746_A750del0.77.7200.0090.000EGFR p.E746_A750del0.0020.000
  • a Human genes: AKT1, v-akt murine thymoma viral oncogene homolog 1; BRAF, B-Raf proto-oncogene, serine/threonine kinase; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog.

  • b NP, no primer available; NA, not available (the S6 plasma cfDNA sample was not analyzed by targeted amplicon sequencing analysis).